Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jan 15;170(2):90-98.
doi: 10.7326/M18-0227. Epub 2018 Dec 18.

Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse

Sean M Murphy  1 , Kathryn E McCollister  2 , Jared A Leff  1 , Xuan Yang  2 , Philip J Jeng  1 , Joshua D Lee  3 , Edward V Nunes  4 , Patricia Novo  3 , John Rotrosen  3 , Bruce R Schackman  1
Affiliations
Randomized Controlled Trial

Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse

Sean M Murphy et al. Ann Intern Med. .

Abstract

Background: Not enough evidence exists to compare buprenorphine-naloxone with extended-release naltrexone for treating opioid use disorder.

Objective: To evaluate the cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone.

Design: Cost-effectiveness analysis alongside a previously reported randomized clinical trial of 570 adults in 8 U.S. inpatient or residential treatment programs.

Data sources: Study instruments.

Target population: Adults with opioid use disorder.

Time horizon: 24-week intervention with an additional 12 weeks of observation.

Perspective: Health care sector and societal.

Interventions: Buprenorphine-naloxone and extended-release naltrexone.

Outcome measures: Incremental costs combined with incremental quality-adjusted life-years (QALYs) and incremental time abstinent from opioids.

Results of base-case analysis: Use of the health care sector perspective and a willingness-to-pay threshold of $100 000 per QALY showed buprenorphine-naloxone to be preferable to extended-release naltrexone in 97% of bootstrap replications at 24 weeks and in 85% at 36 weeks. Similar results were obtained with incremental time abstinent from opioids as an outcome and with use of the societal perspective.

Results of sensitivity analysis: The base-case results were sensitive to the cost of the 2 treatments and the success of randomized treatment initiation.

Limitation: Relatively short follow-up for a chronic condition, substantial missing data, no information on patient out-of-pocket and social service costs.

Conclusion: Buprenorphine-naloxone is preferred to extended-release naltrexone as first-line treatment when both options are clinically appropriate and patients require detoxification before initiating extended-release naltrexone.

Primary funding source: National Institute on Drug Abuse, National Institutes of Health.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cost-effectiveness acceptability curves (extended-release naltrexone vs. buprenorphine-naloxone)—intention-to-treat sample. Vertical lines represent recommended value thresholds (29). Willingness-to-pay thresholds are reported in 2016 U.S. dollars per QALY. QALY = quality-adjusted life-year.
Figure 2.
Figure 2.
Cost-effectiveness acceptability curves (extended-release naltrexone vs. buprenorphine-naloxone)—per protocol sample. Vertical lines represent recommended value thresholds (29). Willingness-to-pay thresholds are reported in 2016 U.S. dollars per QALY. QALY = quality-adjusted life-year.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2016 (GBD 2016) data resources. 2017. Accessed at http://ghdx.healthdata.org/gbd-2016 on 12 November 2017.
    1. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204:74–83. [PMID: ] doi:10.1093/infdis/jir196 - DOI - PMC - PubMed
    1. Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol. 2017;27:238–43. [PMID: ] doi:10.1016/j.annepidem.2017.02.003 - DOI - PMC - PubMed
    1. Gruber SA, Silveri MM, Yurgelun-Todd DA. Neuropsychological consequences of opiate use. Neuropsychol Rev. 2007;17:299–315. [PMID: ] - PubMed
    1. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician. 2010;13:401–35. [PMID: ] - PubMed

Publication types

MeSH terms